Clovis Oncology, Inc. (CLVS)
(Delayed Data from NSDQ)
$18.95 USD
+0.51 (2.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.95 USD
+0.51 (2.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Pfizer (PFE) Begins Dosing in Prostate Cancer Drugs Study
by Zacks Equity Research
Pfizer (PFE) is developing its oral PARP inhibitor, talazoparib (Talzenna), in combination with Xtandi as a potential treatment for castration-sensitive prostate cancer in a late-stage study.
Clovis (CLVS) Down 5.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Clovis Oncology (CLVS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of 11.11% and -15.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Clovis (CLVS) Up 4.4% Since Last Earnings Report?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are Options Traders Betting on a Big Move in Clovis Oncology (CLVS) Stock?
by Radhika Saraogi
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Clovis (CLVS) Stock Jumps 47.7%: Will It Continue to Soar?
by Zacks Equity Research
Clovis (CLVS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Clovis (CLVS) Q4 Earnings Miss, Revenues Beat, Stock Down
by Zacks Equity Research
Clovis (CLVS) reports wider-than-expected loss for fourth-quarter 2020. Sales of the company's sole marketed drug, Rubraca, increase year over year.
Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion (ALXN) is set to provide updates on revenues and earnings when it releases fourth-quarter 2020 results on Feb 4.
Clovis (CLVS) Seeks Permission for Clinical Study on Novel Drug
by Zacks Equity Research
Clovis (CLVS) submits regulatory application to the FDA for initiating clinical study on its peptide-targeted radionuclide therapy, FAP-2286.
Company News for Dec 22, 2020
by Zacks Equity Research
Companies in the news are: LESL, RP, AJRD, CLVS
Clovis' (CLVS) Rubraca Confirmatory Study Meets Endpoint
by Zacks Equity Research
Clovis' (CLVS) Rubraca achieves significant improvement in progression free survival compared to chemotherapy in late-stage confirmatory study for BRCA-mutated ovarian cancer indication.
Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Clovis (CLVS) Up 18.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Clovis (CLVS) Q3 Earnings Top, Sales Show Coronavirus Impact
by Zacks Equity Research
Clovis (CLVS) reports mixed third-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares plunge.
Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of 11.88% and -8.42%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaxo's Zejula Gets Positive CHMP View for First-Line Setting
by Zacks Equity Research
The CHMP's favorable response recommends the regulatory nod for GlaxoSmithKline's (GSK) Zejula as the first-line maintenance treatment of ovarian cancer patients regardless of the biomarker status.
Are Options Traders Betting on a Big Move in Clovis Oncology (CLVS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Clovis (CLVS) Down 17.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Clovis (CLVS) Q2 Earnings Lag, Revenues Show Coronavirus Impact
by Zacks Equity Research
Clovis (CLVS) reports dismal second-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares down.
Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of -8.82% and -10.67%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Clovis Oncology (CLVS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clovis (CLVS) Upgraded to Buy: Here's Why
by Zacks Equity Research
Clovis (CLVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Clovis Oncology (CLVS) Stock a Solid Choice Right Now?
by Zacks Equity Research
Clovis Oncology (CLVS) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.